News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
861,024 Results
Type
Article (87438)
Company Profile (760)
Press Release (772803)
Multimedia
Podcasts (173)
Webinars (28)
Section
Business (233057)
Career Advice (4139)
Deals (39795)
Drug Delivery (137)
Drug Development (91251)
Employer Resources (203)
FDA (18285)
Job Trends (17399)
News (397397)
Policy (39926)
Tag
Academia (3005)
Academic (2)
Accelerated approval (18)
Adcomms (35)
Allergies (125)
Alliances (56979)
ALS (146)
Alzheimer's disease (1680)
Antibody-drug conjugate (ADC) (244)
Approvals (18309)
Artificial intelligence (492)
Autoimmune disease (76)
Automation (27)
Bankruptcy (406)
Best Places to Work (12633)
BIOSECURE Act (23)
Biosimilars (161)
Biotechnology (484)
Bladder cancer (132)
Brain cancer (52)
Breast cancer (508)
Cancer (3974)
Cardiovascular disease (339)
Career advice (3557)
Career pathing (38)
CAR-T (247)
CDC (57)
Cell therapy (686)
Cervical cancer (33)
Clinical research (75542)
Collaboration (1391)
Company closure (4)
Compensation (939)
Complete response letters (59)
COVID-19 (2957)
CRISPR (81)
C-suite (593)
Cystic fibrosis (136)
Data (4508)
Decentralized trials (2)
Denatured (62)
Depression (112)
Diabetes (455)
Diagnostics (7093)
Digital health (37)
Diversity (11)
Diversity, equity & inclusion (49)
Drug discovery (236)
Drug pricing (190)
Drug shortages (36)
Duchenne muscular dystrophy (204)
Earnings (98807)
Editorial (54)
Employer branding (25)
Employer resources (171)
Events (133016)
Executive appointments (992)
FDA (20756)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (6)
Frontotemporal dementia (14)
Funding (1256)
Gene editing (173)
Generative AI (48)
Gene therapy (546)
GLP-1 (1021)
Government (5384)
Grass and pollen (7)
Guidances (343)
Healthcare (20937)
HIV (48)
Huntington's disease (38)
IgA nephropathy (63)
Immunology and inflammation (242)
Immuno-oncology (20)
Indications (53)
Infectious disease (3198)
Inflammatory bowel disease (188)
Inflation Reduction Act (15)
Influenza (97)
Intellectual property (192)
Interviews (815)
IPO (17926)
IRA (59)
Job creations (5197)
Job search strategy (2865)
Kidney cancer (16)
Labor market (77)
Layoffs (641)
Leadership (34)
Legal (10148)
Liver cancer (92)
Longevity (12)
Lung cancer (573)
Lymphoma (265)
Machine learning (30)
Management (66)
Manufacturing (639)
MASH (140)
Medical device (14871)
Medtech (14894)
Mergers & acquisitions (22746)
Metabolic disorders (1160)
Multiple sclerosis (138)
NASH (23)
Neurodegenerative disease (230)
Neuropsychiatric disorders (61)
Neuroscience (2719)
NextGen: Class of 2025 (7687)
Non-profit (5096)
Now hiring (57)
Obesity (559)
Opinion (312)
Ovarian cancer (135)
Pain (166)
Pancreatic cancer (172)
Parkinson's disease (242)
Partnered (30)
Patents (421)
Patient recruitment (313)
Peanut (57)
People (66265)
Pharmaceutical (144)
Pharmacy benefit managers (27)
Phase I (23303)
Phase II (32788)
Phase III (24705)
Pipeline (2733)
Policy (295)
Postmarket research (3554)
Preclinical (10501)
Press Release (72)
Prostate cancer (201)
Psychedelics (52)
Radiopharmaceuticals (282)
Rare diseases (677)
Real estate (7421)
Recruiting (78)
Regulatory (28020)
Reports (65)
Research institute (2690)
Resumes & cover letters (651)
Rett syndrome (16)
RNA editing (15)
RSV (71)
Schizophrenia (135)
Series A (207)
Series B (156)
Service/supplier (30)
Sickle cell disease (80)
Special edition (25)
Spinal muscular atrophy (170)
Sponsored (40)
Startups (4318)
State (2)
Stomach cancer (17)
Supply chain (100)
Tariffs (95)
The Weekly (109)
Vaccines (1048)
Venture capital (66)
Weight loss (396)
Women's health (59)
Worklife (21)
Date
Today (173)
Last 7 days (742)
Last 30 days (2614)
Last 365 days (33576)
2025 (26560)
2024 (38142)
2023 (42568)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1280)
Alabama (80)
Alaska (7)
Arizona (302)
Arkansas (14)
Asia (50982)
Australia (8959)
California (9467)
Canada (2868)
China (905)
Colorado (402)
Connecticut (424)
Delaware (271)
Europe (117129)
Florida (1394)
Georgia (316)
Hawaii (3)
Idaho (67)
Illinois (813)
India (51)
Indiana (462)
Iowa (19)
Japan (325)
Kansas (124)
Kentucky (38)
Louisiana (20)
Maine (78)
Maryland (1278)
Massachusetts (7131)
Michigan (314)
Minnesota (563)
Mississippi (4)
Missouri (119)
Montana (33)
Nebraska (26)
Nevada (108)
New Hampshire (77)
New Jersey (2634)
New Mexico (32)
New York (2579)
North Carolina (1412)
North Dakota (10)
Northern California (4284)
Ohio (297)
Oklahoma (22)
Oregon (50)
Pennsylvania (1970)
Puerto Rico (19)
Rhode Island (46)
South America (1655)
South Carolina (49)
South Dakota (1)
Southern California (3617)
Tennessee (149)
Texas (1485)
United States (35023)
Utah (283)
Virginia (249)
Washington D.C. (83)
Washington State (819)
West Virginia (4)
Wisconsin (97)
Wyoming (1)
There are 861,024 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
selectION Demonstrates Safety and Disease-Modifying Mechanism of Action of its Investigational Drug, si-544, in Phase 1b Proof-of-Concept Trial in Psoriasis, a T Cell-Mediated Autoimmune Disease
October 21, 2025
·
1 min read
Press Releases
Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027
October 21, 2025
·
8 min read
Press Releases
Optimi Health Provides Corporate Update
October 21, 2025
·
5 min read
Press Releases
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
October 21, 2025
·
4 min read
C-suite
Novo Foundation Replaces Pharma’s Board, Revealing Deep Divisions Over Leadership
Seven Novo Nordisk board members have resigned. The new board headed by former Novo Nordisk CEO Lars Rebien Sørensen will align behind the new CEO’s massive restructuring plan.
October 21, 2025
·
4 min read
·
Annalee Armstrong
Neuropsychiatric disorders
Neuphoria’s Social Anxiety Drug Flunks Late-Stage Trial
The company is dropping its social anxiety disorder program but will still test the molecule in post-traumatic stress disorder.
October 21, 2025
·
2 min read
·
Dan Samorodnitsky
FDA
Krystal Biotech’s FDA Platform Designation Pushes Limits of the Award
The company’s technology, a modified herpes simplex virus used to deliver gene therapies, was given the FDA’s new designation based on its approved topical skin cream. What this will mean for Krystal’s still-in-development eye drop is unclear.
October 21, 2025
·
2 min read
·
Dan Samorodnitsky
IN PARTNERSHIP WITH ELEMENT
Cost Control to Capability Building: Rethinking Supply and Strategy in Pharma
In this episode presented by Element Materials Technology, guests Dr. Jihye Jang-Lee and Dr. Khanh Courtney will explore how healthcare and pharmaceutical players are rethinking their strategies amid global supply chain disruption.
October 21, 2025
·
1 min read
·
BioSpace Insights
Cell therapy
Galapagos Exits Cell Therapy, Cuts 365 Employees
Galapagos at the start of the year had planned to split into two businesses, with one resulting entity focused on cell therapies. The biotech nixed these plans a few months later, instead choosing to put up for sale multiple cell therapy assets.
October 21, 2025
·
2 min read
·
Tristan Manalac
Cancer
Exelixis’ Kinase Blocker Sets ‘New Survival Bar’ in Third-Line Colorectal Cancer, Opening Road to FDA
With data from the Phase III STELLAR-303 study in the books, Exelixis is plotting a 2025 regulatory application for zanzalintinib.
October 21, 2025
·
2 min read
·
Tristan Manalac
1 of 86,103
Next
